Medical Advocates

HIV Drug Monitoring
 
Main Page

New and Noteworthy
Guidelines
General Reports
Economics
Drug-Specific Studies
Genotype Tests
Phenotype Tests
Special Populations
 

 


Home Page Main New/Newsworthy  Home Page      

This web page is best viewed by using INTERNET EXPLORER
Last Update:  December 15, 2017

 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
     

December  2017
 

General Reports
       


    Journal Papers, Abstracts, and Commentaries
 
 

Chromatographic Methods in HIV Medicine: Application to Therapeutic Drug Monitoring.
Archibald TL, Murrell DE, Brown SD.
Biomed Chromatogr. 2017 Dec 14.
Abstract

A European multicientre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBAS® TAQMAN® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay.
Braun P, Delgado R, Drago M,  et alJ
 Clin Virol
. 2017 May 11;92:75-82
Abstract

Less frequent CD4 monitoring in virologically suppressed HIV.
McMahon J, Crowe SM."
Lancet HIV
. 2017 Apr 11.
Abstract

FULL-TEXT ARTICLE
Incremental Yield of Including Determine-TB LAM Assay in Diagnostic Algorithms for Hospitalized and Ambulatory HIV-Positive Patients in Kenya.
Huerga H, Ferlazzo G, Bevilacqua P, et al
PLoS One. 2017 Jan 26;12(1):e0170976
Paper

Significance of HCV RNA monitoring in the era of new potent therapies.
Wiesmann F, Braun P.
Expert Rev Anti Infect Ther. 2016 Jul 17
Abstract

FULL-TEXT ARTICLE
Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2.
Zbinden A, Dürig R, Shah C,
PLoS One
. 2016 Jun 16;11(6):e0157690.
Paper

Multi-site clinical evaluation of the Xpert HIV-1 viral load assay.
Jordan JA, Plantier JC, Templeton K, Wu AH.
J Clin Virol
.
2016 Apr 26;80:27-32.
Abstract

Evaluation of HIV-1 RealTime, Xpert HIV-1 and Aptima HIV-1 Quant Dx assays in comparison to the NucliSens EasyQ v2.0 HIV-1 assay for quantification of HIV-1 viral load.
Mor O, Gozlan Y, Wax M, et al
J Clin Microbiol. 2015 Aug 19
Abstract

FULL-TEXT ARTICLE
Evaluation of the NucliSens EasyQ v2.0 Assay in Comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in Quantification of C-Clade HIV-1 in Plasma.
Muenchhoff M, Madurai S, Hempenstall AJ, et al
PLoS One. 2014 Aug 26;9(8):e103983.  
Paper

Cross-clade Ultrasensitive PCR-based Assays to Measure HIV Persistence in Large Cohort Studies.
Vandergeeten C, Fromentin R, Merlini E, et al
J Virol
. 2014 Aug 13.
Abstract

FULL-TEXT ARTICLE
Determination of viral tropism by genotyping and phenotyping assays in Brazilian HIV-1-infected patients.
Arruda LB, Araújo ML, Martinez ML, et al
Rev Inst Med Trop Sao Paulo. 2014 Jul;56(4):287-90
Paper

Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients.
Perrone V, Cattaneo D, Radice S, et al
Clinicoecon Outcomes Res. 2014 Jul 14;6:341-8.
Abstract

HIV Drug Resistance Testing Still Important.
de Mendoza C.
AIDS Rev
. 2014 Jan-Mar;16(1):54-5.
Abstract

Comparative performance of HIV-1 RNA load assays at low viral load levels: Results of an international collaboration.
Swenson LC, Cobb B, Geretti AM,  et al
J Clin Microbiol
.
2013 Dec 4.
Abstract

Quantitation of HIV DNA integration: effects of differential integration site distributions on Alu-PCR assays.
Brady T, Kelly BJ, Male F,  et al
J Virol Methods. 2013 Jan 21.
Abstract

FULL-TEXT ARTICLE
Quantification of Reverse Transcriptase Activity by Real-Time PCR as a Fast and Accurate Method for Titration of HIV, Lenti- and Retroviral Vectors
Vermeire J, Naessens E, Vanderstraeten H, et al
PLoS One
. 2012;7(12):e50859.
Paper

FULL-TEXT ARTICLE
Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate?
Arnedo M, Alonso E, Eisenberg N, et al
PLoS One
. 2012;7(12):e47391.
Paper

The Advantages of Therapeutic Drug Monitoring in Patients Receiving Antiretroviral Treatment and Experiencing Medication-Related Problems.
Schoenenberger JA, Aragones AM, Cano SM, et al
Ther Drug Monit
. 2012 Nov 26
Abstract

FULL-TEXT ARTICLE
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors
as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing.
Hoffmann D, Garcia AD, Harrigan PR, et al
PLoS One
. 2011;6(7):e22019.
Paper

FULL-TEXT ARTICLE
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell
Count in HIV-1 Infection before Starting Antiretroviral Therapy.

Buclin T, Telenti A, Perera R,  et al
PLoS One. 2011 Apr 8;6(4):e18578
Paper

Adherence to HIV Therapeutic Drug Monitoring Guidelines in The Netherlands.
van Luin M, Wit FW, Smit C,  et al

Ther Drug Monit. 2010 Dec 29.
Abstract

HIV Drug Resistance Testing.
Cane P.

Methods Mol Biol
. 2011;665:123-32
Abstract

Real-Time Adherence Monitoring for HIV Antiretroviral Therapy.
Haberer JE, Kahane J, Kigozi I, et al

AIDS Behav
. 2010 Aug 31.
Abstract

Pharmacogenetic testing and therapeutic drug monitoring are complementary tools
for optimal individualization of drug therapy.
Gervasini G, Benítez J, Carrillo JA.

Eur J Clin Pharmacol
. 2010 Aug;66(8):755-74
Abstract

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy
regimens for treatment failure in adults and adolescents living with HIV in low-resource
settings.
Chang LW, Harris J, Humphreys E.
Cochrane Database Syst Rev
. 2010 Apr 14;4:CD008494
Abstract

Therapeutic drug monitoring in highly active antiretroviral therapy.|
Liu X, Ma Q, Zhang F.
Expert Opin Drug Saf. 2010 Mar 30.
Abstract

Evaluation of an upgraded version of the Roche COBAS AmpliPrep
/COBAS TaqMan HIV-1 Test for HIV-1 viral load quantification.
Damond F, Avettand-Fenoel V, Collin G, et al

 J Clin Microbiol
. 2010 Feb
Abstract


General Efficacy Studies
       


Introduction to HIV Resistance Testing
David Spach, MD

 
     

Economics
       

     Journal Papers, Abstracts, and Commentaries

 
FULL-TEXT ARTICLE
Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings.
Phillips A, Cambiano V, Nakagawa F, et al
PLoS One
. 2014 Oct 7;9(10):e10
Paper

Should Resistance Testing Be Performed for Treatment-Naive HIV-Infected Patients? A Cost-
Effectiveness Analysis.
Sax PE, Islam R, Walensky RP, et al
 
Clin Infect Dis.
2005 Nov 1;41(9):1316-23.
Abstract

Assessing resistance costs of antiretroviral therapies via measures of future drug
options.
Jiang H, Deeks SG, Kuritzkes DR 

J Infect Dis
. 2003 Oct 1;188(7):1001-8.
Abstract


Special Populations
       

Adolescents
 
     Journal Papers, Abstracts, and Commentaries
 
 
Can Therapeutic Drug Monitoring Improve Pharmacotherapy of
HIV Infection in Adolescents?
Rakhmanina NY, van den Anker JN, Soldin SJ, et al
T
her Drug Monit
. 2010 May 4

Abstract
 
Children
 
     Journal Papers, Abstracts, and Commentaries
 
 
  The Role of Therapeutic Drug Monitoring in Pediatric HIV/AIDS.
Burger DM.

Ther Drug Monit
. 2010 May 4

Abstract


Home Page Main New/Newsworthy  Home Page      

HIV Drug Monitoring Main Page